Exclusive report by Arterial Network
Shenzhen, China – OptoSeeker, a global leader in cell screening and functional characterization platforms (hereinafter "OptoSeeker"), recently announced the completion of an Angel+ funding round raising tens of millions of yuan. The round was led by InnoAngel Fund, with participation by Nanshan Capital, Hedings Venture Capital, Lingyi Capital, and Shanghai Angel Partners. Proceeds will advance OptoSeeker’s optoelectronic microfluidics product line, fund BioMEMS development, expand market networks, and enhance service ecosystems – accelerating the domestic production of premium life science instruments.
As one of few companies globally mastering core optoelectronic tweezer (OET) technology, OptoSeeker delivers high-throughput, high-efficiency cell screening tools at reduced costs. Its interdisciplinary R&D team – comprising academic scientists and industry engineers – has achieved the critical transition from prototype to mass production. The company independently develops hardware, software, and consumables, applying OET and microfluidics to life sciences, materials science, and nanotechnology.
Headquartered in Shenzhen’s Nanshan District, OptoSeeker integrates expertise across optics, mechanics, electronics, automation, analytical chemistry, and software engineering. Its R&D center enables full-stack localization of OET instruments while driving AI and big data innovations for rapid product iteration. The manufacturing facility ensures scalable production of modules, instruments, and consumables with uncompromised stability.
Cell screening remains pivotal in antibody discovery, cell line development, multi-omics research, drug screening, and extracellular detection. OptoSeeker’s OptoBot® series offers China’s first fully localized OET solutions for both research and industrial clients. Modular chip consumables accommodate varying throughput needs, delivering premium services at accessible costs.
(Image: Left-OptoBot®500 | Right-OptoBot®1000)
Beyond OET systems, OptoSeeker’s diversified portfolio includes BioMEMS platforms: the structured-light projection system OptoNeuroBot® and digital microfluidics platform DropletBot®. Both platforms have secured multiple orders since launch, demonstrating robust growth. The company now accelerates global expansion through a dual-track "Domestic + International" strategy.
(Image: Left-OptoNeuroBot® | Right-DropletBot®)
Executive Perspectives
Xie Hainan, Co-founder & CEO of OptoSeeker:
"We deeply appreciate our investors’ steadfast support and our team’s execution excellence. Market adoption of OptoBot®500 has exceeded expectations. We’ll intensify promotion while accelerating OptoBot®1000/2000 launches. Through relentless innovation, we’ll deliver true domestic alternatives for automated cell culture and screening."
Zhu Xiaocheng, Managing Partner at InnoAngel Fund:
"InnoAngel actively scouts life science breakthroughs. OptoSeeker’s academic-industrial team exhibits exceptional R&D and commercialization capabilities. Their OET platforms innovate antibody discovery, CGT, and synthetic biology workflows – we anticipate more transformative solutions."
Xiao Qing, Investment Director at Nanshan Capital:
"OptoSeeker fills critical gaps in domestic high-end instruments with proprietary OET and cross-disciplinary R&D. Their cost-efficient precision tools empower antibody and gene therapy development, aligning perfectly with Shenzhen’s hard-tech ecosystem. We endorse their global vision to become China’s scientific instrument flagship."
Huang Xiaozhong, Investment Director at Hedings Venture Capital:
"Scientific instrumentation demands long-term accumulation. Supply chain constraints plague labs and downstream users. As China’s sole OET core tech holder, OptoSeeker will overcome bottlenecks to achieve instrument sovereignty for biopharma."
Zheng Lianfa, Partner at Lingyi Capital:
"Life science innovations like CRISPR, single-cell sequencing, and AI diagnostics require cutting-edge instruments. We champion OptoSeeker’s product innovation capabilities.
Investor Profiles
InnoAngel Fund
Founded in April 2013 with multi-billion RMB AUM, InnoAngel has backed 500+ startups in IT, new energy, advanced manufacturing, and biotech. It focuses on Angel/Pre-A stages, committed to being entrepreneurs’ first check.
Nanshan Capital
A state-backed VC under Shenzhen Nanshan SASAC, managing 5B+ RMB funds. Key investments include Dynanonic, Winlaser, Cambricon, and MicroPoint Biotech. Focus: IT, smart manufacturing, healthcare, and new materials.
Hedings Venture Capital
Invests in China’s strategic needs: AI, advanced manufacturing, new energy, biomedicine, and semiconductors. Primarily targets Seed-to-Series A with "patient capital" philosophy.
Lingyi Capital
Early-stage VC founded in 2022 with 1B+ RMB AUM. Backed by seasoned investors and listed company founders, it focuses on hard tech, healthcare, and AI.
Shanghai Angel Partners
Platform established under Shanghai government guidance to foster angel investment in hard tech and scientific commercialization.
